Gain Therapeutics, Inc. GANX 深 沪
已收盘 02-06 16:00:00 美东时间
1.75
+0.130
+8.02%
华盛通- 最 高1.82
- 今 开1.63
- 成交量 69.24万股
- 最 低 1.63
- 昨 收 1.62
- 总市值 6730.86万
- 52周最高 4.34
- 市盈率 静 --
- 换手率 1.80%
- 52周最低 1.41
- 委 比 26.70%
- 总股本 3846.21万
- 历史最高 17.93
- 量 比 1.19
- 振 幅 11.73%
- 历史最低 0.89
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
Gain Therapeutics announced its participation in several key events during the 44th Annual J.P. Morgan Healthcare Conference, including the Sachs Neuroscience Innovation Forum, the Demy-Colton/Informa Biotech Showcase, and the LifeSci Advisors Corporate Access Event. The company highlighted its lead drug candidate, GT-02287, which is in clinical development for treating Parkinson’s disease with or without a GBA1 mutation. GT-02287 is an allosteri...
01-07 12:00
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
Gain Therapeutics announced positive results from its Phase 1b clinical study of GT-02287 for Parkinson's disease (PD). In patients with elevated cerebrospinal fluid (CSF) glucosylsphingosine (GluSph), levels decreased by 81% after 90 days of treatment, indicating increased GCase enzyme activity and potential disease modification. Of the 19 participants, 15 showed average improvements in Movement Disorder Society Unified Parkinson’s Disease Ratin...
01-06 12:00
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Shares of GH Research PLC (NASDAQ:GHRS) rose sharply in pre-market trading afte...
01-05 17:27
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
美股牛股 | 太空概念股普涨，LUNR涨近38%；爱美医疗涨超30%，获拜玛林制药48亿美元收购
NovaBay Pharmaceuticals涨79.7%；Lunar Corporation涨37.7%；D-MARKET Electronic Services & Trading涨37.1%
2025-12-20 10:49
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Athira Pharma (NASDAQ:ATHA) stock rose 70.0% to $7.03 during Thursday'...
2025-12-19 01:06
Gain Therapeutics Reports Encouraging Phase 1b Parkinson’s Data
An update from Gain Therapeutics ( ($GANX) ) is now available. On December 18, ...
2025-12-18 22:27
Gain Therapeutics Reports Early Parkinson's Study Showing Brain Biomarker Improvement After 90 Days Of Treatment
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided
2025-12-18 20:05
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
Gain Therapeutics reported that GT-02287, a GCase modulator, reduced glucosylsphingosine (GluSph) levels in cerebrospinal fluid (CSF) of Parkinson's disease (PD) patients, indicating increased GCase activity in the brain and potential to slow PD progression. A virtual KOL event is scheduled for January 6, 2026, to discuss the results. The Phase 1b study enrolled 21 participants, with 15 continuing to a nine-month extension. GT-02287 showed favora...
2025-12-18 12:00
Gain Therapeutics Announces New Stock Offering Program
The latest announcement is out from Gain Therapeutics ( ($GANX) ). Gain Therape...
2025-11-29 05:31
